Alnylam Pharmaceuticals
ALNY
#534
Rank
$40.15 B
Marketcap
$307.99
Share price
1.09%
Change (1 day)
92.03%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Revenue for Alnylam Pharmaceuticals (ALNY)

Revenue in 2025 (TTM): $2.34 Billion USD

According to Alnylam Pharmaceuticals 's latest financial reports the company's current revenue (TTM ) is $2.34 Billion USD. In 2024 the company made a revenue of $2.24 Billion USD an increase over the revenue in the year 2023 that were of $1.82 Billion USD. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Alnylam Pharmaceuticals from 2004 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) $2.34 B4.44%
2024 $2.24 B22.97%
2023 $1.82 B76.23%
2022 $1.03 B22.88%
2021 $0.84 B71.31%
2020 $0.49 B124.28%
2019 $0.21 B193.36%
2018 $74.9 M-16.69%
2017 $89.91 M90.66%
2016 $47.15 M14.75%
2015 $41.09 M-18.72%
2014 $50.56 M7.2%
2013 $47.16 M-29.31%
2012 $66.72 M-19.37%
2011 $82.75 M-17.28%
2010 $0.10 B-0.49%
2009 $0.10 B4.54%
2008 $96.16 M88.94%
2007 $50.89 M89%
2006 $26.93 M371.13%
2005 $5.71 M33.61%
2004 $4.27 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Arrowhead Pharmaceuticals
ARWR
$0.54 B-76.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
$14.08 B 499.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
$2.23 B-4.89%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
$0.68 B-70.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
$53.22 B 2,166.60%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
$47.43 B 1,920.06%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
$16.61 B 607.59%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel